Boston Scientific snaps up nVision Medical in deal worth $275M

Boston Scientific HQ
Boston Scientific will make a cash payment of $150 million, with another $125 million slated to be paid at certain milestones. (Boston Scientific)

Boston Scientific is shelling out up to $275 million to acquire nVision Medical, the developer of the first and only FDA-approved device to collect cells from fallopian tubes used for early detection of ovarian cancer.

Under terms of the sale, Boston Scientific will make a cash payment of $150 million, with another $125 million slated to be paid when certain milestones are reached in the next four years. The company said the purchase isn’t expected to have a material impact on the bottom line on an adjusted basis in 2018 and 2019.

Early research has shown the nVision device effectively collects cells that, after being tested, correlate with a postsurgery definitive diagnosis of ovarian cancer. Boston Scientific said it will begin additional clinical research with the device to determine how the cells collected from the fallopian tubes can be used to make a diagnosis before surgery and help in the decision-making process for women at increased risk for ovarian cancer.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

"We estimate the near-term market opportunity to be $500 million with the potential to grow to $2 billion as this device is used by more gynecologists to help even more women," Dave Pierce, executive vice president and president, MedSurg, Boston Scientific, said in a statement. "We are committed to expanding our women's health portfolio and driving clinical research that will help deliver innovative options for the prevention and treatment of gynecological cancer."

nVision's microcatheter technology allows doctors to access a patient's fallopian tubes in the office without the need of any incisions or general anesthesia. The tech is focused in two areas: cell collection from the fallopian tubes and direct visualization of fallopian tube lumen.

Ovarian cancer is the fifth leading cause of cancer death among women, and the Mayo Clinic estimates that more than two million women in the U.S. are at high risk for developing the disease, which occurs more frequently in those with a family history or with BRCA1 or 2 gene mutations.

Suggested Articles

What the NASH field needs, says Genfit CEO Pascal Prigent, is something like the Hb1Ac test for diabetes.

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Exact Sciences received an FDA breakthrough designation for its liver cancer blood test as it finalized its $2.8 billion merger with Genomic Health.